The patent will grant OphthaliX exclusive rights for the use of drug candidate CF101 for the treatment of dry eye syndrome in the People’s Republic of China until February 2026.
CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a proven efficacy in Phase II clinical studies and an excellent safety profile.
OphthaliX interim CEO and Chairman Pnina Fishman said they are currently enrolling patients for the ongoing Phase III multinational study of the pioneered oral drug for the treatment of dry eye syndrome.
"We are delighted that the Chinese SIPO granted us this important patent covering the use of CF101 for dry eye syndrome in China, reflecting the innovation of CF101 in the ophthalmology field," Fishman added.